The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux

References

• Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD, Newcomb PA. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 2013; 108:1757-64; PMID:23511557; http://dx.doi.org/10.1038/bjc.2013.118
   PubMed Web of Science ®Google Scholar
• Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486:532-6; PMID:22722830
   PubMed Web of Science ®Google Scholar
• Charette N, Vandeputte C, Starkel P. Ras in digestive oncology: from molecular biology to clinical implications. Curr Opin Oncol 2014; 26:454-61; PMID:24849046; http://dx.doi.org/10.1097/CCO.0000000000000088
   PubMed Web of Science ®Google Scholar
• Grothey A, Van CE, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303-12; PMID:23177514; http://dx.doi.org/10.1016/S0140-6736(12)61900-X
   PubMed Web of Science ®Google Scholar
• Magudia K, Lahoz A, Hall A. K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc. J Cell Biol 2012; 198:185-94; PMID:22826122; http://dx.doi.org/10.1083/jcb.201202108
   PubMed Web of Science ®Google Scholar
• Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 2008; 8:835-50; PMID:18948996; http://dx.doi.org/10.1038/nrc2521
   PubMed Web of Science ®Google Scholar
• Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer 2012; 12:23-38; PMID:NOT_FOUND
   PubMed Web of Science ®Google Scholar
• Schneider D, Greb C, Koch A, Straube T, Elli A, Delacour D, Jacob R. Trafficking of galectin-3 through endosomal organelles of polarized and non-polarized cells. Eur J Cell Biol 2010; 89:788-98; PMID:20705359; http://dx.doi.org/10.1016/j.ejcb.2010.07.001
   PubMed Web of Science ®Google Scholar
• Straube T, von MT, Honig E, Greb C, Schneider D, Jacob R. pH-dependent recycling of galectin-3 at the apical membrane of epithelial cells. Traffic 2013; 14:1014-27; PMID:23710780; http://dx.doi.org/10.1111/tra.12086
   PubMed Web of Science ®Google Scholar
• Lakshminarayan R, Wunder C, Becken U, Howes MT, Benzing C, Arumugam S, Sales S, Ariotti N, Chambon V, Lamaze C et al. Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers. Nat Cell Biol 2014; 16:595-606; PMID:24837829; http://dx.doi.org/10.1038/ncb2970
   PubMed Web of Science ®Google Scholar
• Thurston TLM, Wandel MP, von Muhlinen N, Foeglein A, Randow F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature 2012; 482:414-8; PMID:22246324; http://dx.doi.org/10.1038/nature10744
   PubMed Web of Science ®Google Scholar
• Mishra R, Grzybek M, Niki T, Hirashima M, Simons K. Galectin-9 trafficking regulates apical-basal polarity in Madin-Darby canine kidney epithelial cells. Proc Natl Acad Sci U S A 2010; 107:17633-8; PMID:20861448; http://dx.doi.org/10.1073/pnas.1012424107
   PubMed Web of Science ®Google Scholar
• Mo D, Costa SA, Ihrke G, Youker RT, Pastor-Soler N, Hughey RP, Weisz OA. Sialylation of N-linked glycans mediates apical delivery of endolyn in MDCK cells via a galectin-9-dependent mechanism. Mol Biol Cell 2012; 23:3636-46; PMID:22855528; http://dx.doi.org/10.1091/mbc.E12-04-0329
   PubMed Web of Science ®Google Scholar
• Wiersma VR, de BM, Helfrich W, Bremer E. Therapeutic potential of Galectin-9 in human disease. Med Res Rev 2013; 33 Suppl 1:E102-26; PMID:21793015; http://dx.doi.org/10.1002/med.20249
   PubMedGoogle Scholar
• Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 2005; 11:2962-8; PMID:15837748; http://dx.doi.org/10.1158/1078-0432.CCR-04-0861
   PubMed Web of Science ®Google Scholar
• Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T, Hirashima M. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 2002; 99:809-16; PMID:12115481; http://dx.doi.org/10.1002/ijc.10436
   PubMed Web of Science ®Google Scholar
• Liang M, Ueno M, Oomizu S, Arikawa T, Shinonaga R, Zhang S, Yamauchi A, Hirashima M. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J Cancer Res Clin Oncol 2008; 134:899-907; PMID:18264727; http://dx.doi.org/10.1007/s00432-008-0352-z
   PubMed Web of Science ®Google Scholar
• Yamauchi A, Kontani K, Kihara M, Nishi N, Yokomise H, Hirashima M. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. Breast J 2006; 12:S196-S200; PMID:16959001; http://dx.doi.org/10.1111/j.1075-122X.2006.00334.x
   PubMed Web of Science ®Google Scholar
• Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, Takeshita K, Niki T, Tominaga A, Yamauchi A, Hirashima M. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 2008; 18:735-44; PMID:18579572; http://dx.doi.org/10.1093/glycob/cwn062
   PubMed Web of Science ®Google Scholar
• Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, Shoji H, Nakamura T. Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett 2005; 579:2058-64; PMID:15811318; http://dx.doi.org/10.1016/j.febslet.2005.02.054
   PubMed Web of Science ®Google Scholar
• Blasco RB, Francoz S, Santamaria D, Canamero M, Dubus P, Charron J, Baccarini M, Barbacid M. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011; 19:652-63; PMID:21514245; http://dx.doi.org/10.1016/j.ccr.2011.04.002
   PubMed Web of Science ®Google Scholar
• Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov 2011; 1:128-36; PMID:22043453; http://dx.doi.org/10.1158/2159-8290.CD-10-0044
   PubMed Web of Science ®Google Scholar
• Wiersma VR, de Bruyn M, van Ginkel RJ, Sigar E, Hirashima M, Niki T, Nishi N, Samplonius DF, Helfrich W, Bremer E. The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells. J Invest Dermatol 2012; 132:2302-5; PMID:22572821; http://dx.doi.org/10.1038/jid.2012.133
   PubMed Web of Science ®Google Scholar
• Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, Kamphorst JJ, Chen G, Lemons JM, Karantza V et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011; 25:460-70; PMID:21317241; http://dx.doi.org/10.1101/gad.2016311
   PubMed Web of Science ®Google Scholar
• Kim MJ, Woo SJ, Yoon CH, Lee JS, An S, Choi YH, Hwang SG, Yoon G, Lee SJ. Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J Biol Chem 2011; 286:12924-32; PMID:21300795; http://dx.doi.org/10.1074/jbc.M110.138958
   PubMed Web of Science ®Google Scholar
• Yoon YH, Cho KS, Hwang JJ, Lee SJ, Choi JA, Koh JY. Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. Invest Ophthalmol Vis Sci 2010; 51:6030-7; PMID:20574031; http://dx.doi.org/10.1167/iovs.10-5278
   PubMed Web of Science ®Google Scholar
• Fehrenbacher N, Bastholm L, Kirkegaard-Sørensen T, Rafn B, Bøttzauw T, Nielsen C, Weber E, Shirasawa S, Kallunki T, J Jäättelä M. Sensitization to the Lysosomal Cell Death Pathway by Oncogene-Induced Down-regulation of Lysosome-Associated Membrane Proteins 1 and 2. Cancer Res 2008; 68:6623-33; PMID:18701486; http://dx.doi.org/10.1158/0008-5472.CAN-08-0463
   PubMed Web of Science ®Google Scholar
• Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, Debnath J. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 2011; 22:165-78; PMID:21119005; http://dx.doi.org/10.1091/mbc.E10-06-0500
   PubMed Web of Science ®Google Scholar
• Strohecker AM, White E. Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism. Autophagy 2014; 10:384-5; PMID:24362353; http://dx.doi.org/10.4161/auto.27320
   PubMed Web of Science ®Google Scholar
• Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, McMahon M, White E. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov 2013; 3:1272-85; PMID:23965987; http://dx.doi.org/10.1158/2159-8290.CD-13-0397
   PubMed Web of Science ®Google Scholar
• Maddodi N, Huang W, Havighurst T, Kim K, Longley BJ, Setaluri V. Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J Invest Dermatol 2010; 130:1657-67; PMID:20182446; http://dx.doi.org/10.1038/jid.2010.26
   PubMed Web of Science ®Google Scholar
• Mancias JD, Kimmelman AC. Targeting autophagy addiction in cancer. Oncotarget 2011; 2:1302-6; PMID:22185891
   PubMed Web of Science ®Google Scholar
• Morgan MJ, Gamez G, Menke C, Hernandez A, Thorburn J, Gidan F, Staskiewicz L, Morgan S, Cummings C, Maycotte P et al. Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent. Autophagy 2014; 10:1814-26; PMID:25136801; http://dx.doi.org/10.4161/auto.32135
   PubMed Web of Science ®Google Scholar
• Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 2010; 1806:220-9; PMID:20637264
   PubMed Web of Science ®Google Scholar
• Lai K, Killingsworth MC, Lee CS. The significance of autophagy in colorectal cancer pathogenesis and implications for therapy. J Clin Pathol 2014; 67:854-8; PMID:25055793; http://dx.doi.org/10.1136/jclinpath-2014-202529
   PubMed Web of Science ®Google Scholar
• Wei MF, Chen MW, Chen KC, Lou PJ, Lin SY, Hung SC, Hsiao M, Yao CJ, Shieh MJ. Autophagy promotes resistance to photodynamic therapy-induced apoptosis selectively in colorectal cancer stem-like cells. Autophagy 2014; 10:1179-92; PMID:24905352; http://dx.doi.org/10.4161/auto.28679
   PubMed Web of Science ®Google Scholar
• Leisching G, Loos B, Botha M, Engelbrecht AM. A nontoxic concentration of Cisplatin induces autophagy in cervical cancer: selective cancer cell death with autophagy inhibition as an adjuvant treatment. Int J Gynecol Cancer 2015; 25:380-388; PMID:25695544; http://dx.doi.org/10.1097/IGC.0000000000000365
   PubMed Web of Science ®Google Scholar
• Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA et al. Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review. Clin Cancer Res 2012; 18:2257-68; PMID:22357840; http://dx.doi.org/10.1158/1078-0432.CCR-11-2410
   PubMed Web of Science ®Google Scholar
• Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Li+¿vre A, Cortet M, Bouvier AM, Rat P et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008; 122:2255-9; PMID:18224685; http://dx.doi.org/10.1002/ijc.23388
   PubMed Web of Science ®Google Scholar
• Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5:526-42; PMID:16069816; http://dx.doi.org/10.1038/nrc1649
   PubMed Web of Science ®Google Scholar
• Nagae M, Nishi N, Nakamura-Tsuruta S, Hirabayashi J, Wakatsuki S, Kato R. Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue. J Mol Biol 2008; 375:119-35; PMID:18005988; http://dx.doi.org/10.1016/j.jmb.2007.09.060
   PubMed Web of Science ®Google Scholar
• Ono K, Hattori H, Uemura K, Nakayama J, Ota H, Katsuyama T. Expression of Forssman antigen in human large intestine. J Histochem Cytochem 1994; 42:659-65; PMID:7512587; http://dx.doi.org/10.1177/42.5.7512587
   PubMed Web of Science ®Google Scholar
• Hakomori S. Tumor-associated carbohydrate antigens. Annu Rev Immunol 1984; 2:103-26; PMID:6085749; http://dx.doi.org/10.1146/annurev.iy.02.040184.000535
   PubMed Web of Science ®Google Scholar
• Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 2008; 214:320-7; PMID:18098337; http://dx.doi.org/10.1002/path.2295
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee C, Foxworth A, Waldman T. B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells. Cancer Res 2004; 64:1932-7; PMID:15026326; http://dx.doi.org/10.1158/0008-5472.CAN-03-3862
   PubMed Web of Science ®Google Scholar
• Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934-4; PMID:12198537; http://dx.doi.org/10.1038/418934a
   PubMed Web of Science ®Google Scholar
• Freeman AK, Ritt DA, Morrison DK. The importance of Raf dimerization in cell signaling. Small GTPases 2013; 4:180-5; PMID:23985533; http://dx.doi.org/10.4161/sgtp.26117
   PubMedGoogle Scholar
• Freeman AK, Ritt DA, Morrison DK. Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling. Mol Cell 2013; 49:751-8; PMID:23352452; http://dx.doi.org/10.1016/j.molcel.2012.12.018
   PubMed Web of Science ®Google Scholar
• Lavoie H, Thevakumaran N, Gavory G, Li JJ, Padeganeh A, Guiral S, Duchaine J, Mao DY, Bouvier M, Sicheri F et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol 2013; 9:428-36; PMID:23685672; http://dx.doi.org/10.1038/nchembio.1257
   PubMed Web of Science ®Google Scholar
• Nobumoto A, Oomizu S, Arikawa T, Katoh S, Nagahara K, Miyake M, Nishi N, Takeshita K, Niki T, Yamauchi A et al. Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin Immunol 2009; 130:322-30; PMID:18974023; http://dx.doi.org/10.1016/j.clim.2008.09.014
   PubMed Web of Science ®Google Scholar
• Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 2008; 181:7660-9; PMID:19017954; http://dx.doi.org/10.4049/jimmunol.181.11.7660
   PubMed Web of Science ®Google Scholar
• Gooden MJ, Wiersma VR, Samplonius DF, Gerssen J, van Ginkel RJ, Nijman HW, Hirashima M, Niki T, Eggleton P, Helfrich W et al. Galectin-9 activates and expands human T-helper 1 cells. PLoS One 2013; 8:e65616-; PMID:23741502; http://dx.doi.org/10.1371/journal.pone.0065616
   PubMed Web of Science ®Google Scholar
• Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le MS, Guigay J, Hirashima M, Guemira F et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009; 113:1957-66; PMID:19005181; http://dx.doi.org/10.1182/blood-2008-02-142596
   PubMed Web of Science ®Google Scholar